Member Info for Hurst10

Ignore question marks

Now 4x on the offer
Real size offer price 128
MM trying to hide
In 30 min alarm clocks will set off in NY
Coffee place off Wall Street opening early ??
Mill+ traded this afternoon.
130-5 by opening bell
??

3x size on the bid

Usual trades about to happen:
MARX and BEGO on the bid
Early start in NY!
130-5 before 07.00 NY

Watch Bid and Offer
BEGO about to join the bid
We will have 4x the amount vs offer on the bid any minute.
Plus 340/ traded on the buy sided since NY 07.00 AM

Look out for BEGO do a reversal and join MARX on the bid.
Look at the volume since 07.00 AM NY time

Just a question, but can one buy options in Avacta

They certainly are!
The easiest IPO this year so far !!!

What is worth bearing in mind is that Avacta has an amazing goldmine in their JV with Daewoong : Affyxell.
As the CEO said: Affyxell uniquely positioned to develop novel and powerful cell therapies through two world class technologies, the Affimer platform and Daewoong’s technology for off the shelf allogenic MSC therapies, are attracting world class partners and investors. GenScript ProBio, a worldwide leader in biopharmaceutical contract development and manufacturing organization (CDMO), today announced the continued partnership with AffyXell Therapeutics, a joint venture of United Kingdom-based Avacta Group and South Korea-based pharmaceutical company, Daewoong Pharmaceutical. This collaboration signifies GenScript ProBio's ongoing commitment to the advancement of novel gene therapies using mesenchymal stem cells for the treatment of autoimmune and inflammatory diseases.
However GenScript ProBio is a spin off from GenScript biotech corp, GenScript Biotech Corporation is the world leading science serving platform by providing reliable, high quality and innovative reagents and instruments with superior customer service to enable customer successes across a wide variety of existing and emerging life science research and development areas.That company also floated Legend Biotech developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell and natural killer (NK) cell-based immunotherapy. From our three R&D sites around the world, we apply these innovative technologies to pursue the discovery of safe, efficacious and cutting-edge therapeutics for patients worldwide.
Avacta is part of something quite special, which in US would attract a valuation way above UK’s current numbers. Yet the analyst covering the stock are not applying any value to this in their SOP.At. current market cap in the U.K., Affyxell could easily attract a valuation higher than the official market cap of Avacta.
So with the AVA machine about to be rolled out and then more news from Affyxell and then news from AACC and the recent hires, well the US brokers will be lining up!!

Great.
Thanks

Would it be possible to have the link so one can follow which hospital are which trials ?
Thanks

Man is oldest person possibly cured of HIV after stem cell transplant

infectious disease news logo
ByGerard Gallagher
Fact checked byCarol L. DiBerardino, MLA, ELS
Source/Disclosures

A 66-year-old man is the oldest person yet to possibly be cured of HIV after undergoing a stem cell transplant, researchers announced Wednesday.

Agree with not using the word “ delay “, when this is a major event, which most likely will be a press event and at the participated hospitals.Lancet etc will be reporting.

Meanwhile the buy/sell ratio continues.
Perhaps if one were to do a SOP, Affyxell,the Diagnostic and the Therapeutic : one would end up with a projected figure slightly higher than this level.
The gene editing /stem cell business worth more than the current m/c of Avacta?

Nasdaq listed !

07.00 am NY time, BEGO will jump on the bid and leave the offer.

Cell and gene therapies are taking the world by storm. With CRISPR gene-editing technology, the genome is no longer an untouchable sacred text. Instead, genomic DNA is actively manipulated in the laboratory and the clinic. This revolution is changing the bench, the bedside, and the boardroom. As a result, the cell and gene therapy market is valued at USD 4.99 billion and is expected to grow to over USD 36 billion by 2027.
Significant upgrade of the est. market size of the cell and gene therapy market!
Affyxell with it’s new shareholders is most likely worth 4x previous valuation done earlier this year.

Agree with the high quality of the new appointments.If you look at Eleftheria Ledaki and via Autolus, her experience with dealing with Nasdaq and in particular Autolus and their analyst coverage by Goldman’s, Kempen and JP Morgan and the company’s dealings with Moderna and Blackstone Life Science.Clearly US listing is around the corner!
Therapeutics day in November should be very interesting and well timed!

We do have Roche diagnostics etc at the conference, sure David Wilson will be busy networking, while Avacta therapeutic is getting ready for C4 at increased dose.
There has been no indication of any slow down or disruption to the ongoing trials!
The US trials would have commenced at the C3 level.Interesting August ahead

Miniaturization enables lower fluid volumes and cost, reduces turnaround time, and increases ease of operation. Current CLIA-waived LoC platforms make use of different microfluidic technologies, including pressure, capillary flow, centrifugal, or electrokinetic effects coupled to external detectors for electrochemical or optical analysis, noted Heather Nelson, PhD, clinical chemistry fellow at ARUP Laboratories.

“In working with this technology, I see how many applications it has and the great potential for both basic research and clinical investigations,” said Nelson.

Nelson will lead a roundtable session “Lab-on-a-Chip Technology: A Driving Force in Point-of-Care Testing” at the AACC 2022 Annual Scientific Meeting and Clinical Lab Expo July 24-28 in Chicago. Specifically, Nelson will lead a discussion among participants regarding experiences encountered with LoC technology and suggestions for further implementation and regulation of the technology in clinical care.